MicroRNAs: Potential biomarkers for disease diagnosis

Bio-Medical Materials and Engineering

Volumn 24, Issue 6, 2014, Pages 3917-3925

  Li, Xu ^a   Xiuli, Qi ^a   Shengliang, Duan ^a   Yumei, Xie ^b   Xinlei, Ren ^a   Gaoyun, Chen ^a   Xiaocong, Yang ^a   Lili, Han ^a   Qirui, Dong ^a  

^a RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (China)

^b ACADEMY OF EQUIPMENT COMMAND AND TECHNOLOGY   (China)

Author keywords

Biomarker; Disease diagnosis; MicroRNA

Indexed keywords

DISEASE DIAGNOSIS; MICRORNAS;

BIOMARKERS;

ASBESTOS; BIOLOGICAL MARKER; GENOMIC DNA; MICRORNA; MICRORNA 106B; MICRORNA 133A; MICRORNA 143; MICRORNA 145; MICRORNA 146A; MICRORNA 18A; MICRORNA 20A; MICRORNA 21; MICRORNA 29A; MICRORNA 92A; MYC PROTEIN; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG; GENETIC MARKER;

ACUTE GRAFT REJECTION; CANCER DIAGNOSIS; CANCER PROGNOSIS; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIABETES MELLITUS; DIAGNOSTIC VALUE; GENE EXPRESSION; HUMAN; OCCUPATIONAL DISEASE; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PREDICTION; ANIMAL; GENETIC MARKER; GENETIC SCREENING; GENETICS; MOLECULAR PATHOLOGY; PROCEDURES;

ANIMALS; BIOLOGICAL MARKERS; GENETIC MARKERS; GENETIC TESTING; HUMANS; MICRORNAS; PATHOLOGY, MOLECULAR;

EID: 84907276870     PISSN: 09592989     EISSN: 18783619     Source Type: Journal    
DOI: 10.3233/BME-141223     Document Type: Conference Paper

References (67)

1. S. Hundt, U. Haug and H. Brenner, Blood markers for early detection of colorectal cancer: a systematic review, Cancer Epidemiol Biomarkers Prev. 16 (2007), 1935-1953.
2. S. Tao, S. Hundt, U. Haug and H Brenner, Sensitivity estimates of blood-based tests for colorectal cancer detection: impact of overrepresentation of advanced stage disease, Am. J. Gastroenterol. 106 (2011), 242-253.
3. D.H. Chitwood and M.C. Timmermans, Target mimics modulates miRNAs, Nat Genet 39 (2007), 935-936.
4. V. Ambros, The functions of animal microRNAs, Nature 431 (2004), 350-355.
5. C.Z. Chen, L. Li, H.F. Lodish et al, MicroRNAs modulate hematopoietic lineage differentiation, Science 303 (2004), 83-86.
6. C. Roldo, E. Missiaglia, J.P. Hagan et al, MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior, J. Clin. Oncol. 24 (2006), 4677-4684.
7. J.J. Zhao, Y.J. Hua, D.G. Sun et al, Genome-wide microRNA profiling in human fetal nervous tissues by oligonucleotide microarray, Childs. Nerv. Syst. 22 (2006), 1419-1425.
8. S. Griffiths-Jones, H.K. Saini, S.V. Dongen and A.J. Enright, MiR Base: tools for microRNA genomics, Nucleic Acids Res. 36 (2008), D154-D158.
9. R.C. Friedman, K.K. Farh, C.B. Burge and D.P. Bartel, Most mammalian mRNAs are conserved targets of microRNAs, Genome Res. 27 (2008), 92-105.
10. D.P. Bartel, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell 116 (2004), 281-297.
11. G.J. Hannon, RNA interference, Nature 418 (2002), 244-251.
12. R.C. Lee, R.L. Feinbaum and V. Ambros, The C. elegan's heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14, Cell 75 (1993), 843-854.
13. D.P. Bartel, MicroRNAs: target reconization and regulatory function, Cell 136 (2009), 215-233.
14. P.D. Zamore and B. Haley, Ribo-gnome: the big world of small RNAs, Science 309 (2005), 1519-1524.
15. S. Komatsu, D. Ichikawa, H. Takeshita, M. Tsujiura, R. Morimura et al., Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma, Br. J. Cancer 105 (2011), 104-115.
16. M.M. Georgescu, PTEN tumor suppressor network in PI3K-Akt pathway control, Genes Cancer 1 (2010), 1170-1177.
17. S. Ali, K. Almhanna, W. Chen, P.A. Philip and F.H. Sarkar, Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer, Am. J. Transl. Res. 3 (2010), 28-47.
18. V. Bihrer, O. Waidmann, M. Friedrich-Rust et al, Serum microRNA-21 as marker for neucroinflammation in hepatitis C patients with and without hepatocellular carcinoma, PLOS One 6 (2011), e26971-1-e26971-7.
19. M. Tsujiura, D. Ichikawa, S. Komatsu et al, Circulating microRNAs in plasma of patients with gastric cancers, Br. J. Cancer 102 (2010), 1174-1183.
20. G.K. Wang, J.Q. Zhu, J.T. Zhang et al., Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans, Eur. Heart J. 31 (2010), 659-666.
21. J. Wei, W. Gao, C.J. Zhu et al., Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of nonsmall cell lung cancer, Chin. J. Cancer 30 (2011), 407-414.
22. F. Yaman Agaoglu, M. Kovancilar, Y. Dizdar et al., Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer, Tumour Biol. 32 (2011), 583-588.
23. X.Y. Luo, S. Christian, B. Barbara and B. Hermann, Identification and evaluation of plasma microRNAs for early detection of colorectal cancer, PLoS One 8 (2013), e62880-1-e62880-9.
24. Z. Huang, D. Huang, S. Ni et al., Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer, Int. J. Cancer 127 (2010), 118-126.
25. Y. Fu, Z. Yi, X. Wu, J. Li and F. Xu, Circulating microRNAs in patients with active pulmonary tuberculosis, J. Clin. Microbiol. 49 (2011), 4246-4251.
26. E.K. Ng, W.W. Chong, H. Jin, E.K. Lam et al., Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening, Gut 58 (2009), 1375-1381.
27. H. Cheng, L. Zhang, D.E. Cogdell et al., Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis, PLoS One 6 (2011), e17745-1-e17745-8.
28. S. Fichtlscherer, S. De Rosa, H. Fox et al., Circulating microRNAs in patients with coronary artery disease, Circ. Res. 107 (2010), 677-684.
29. R. Morimura, S. Komatsu, D. Ichikawa et al., Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer, Br. J. Cancer 105 (2011), 1733-1740.
30. M. Shigoka, A. Tsuchida, T. Matsudo et al., Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development, Pathol Int. 60 (2010), 351-357.
31. S. Tao, U. Haug, K. Kuhn and H. Brenner, Comparison and combination of blood-based inflammatory markers with faecal occult blood tests for noninvasive colorectal cancer screening, Br. J. Cancer 106 (2012), 1424-1430.
32. M. Tanaka, K. Oikawa, M. Takanashi et al., Downregulation of miR-92 in human plasma is a novel marker for acute leukemia patients, PLoS One 4 (2009), e5532-1-e5532-5.
33. L. Cui, Y. Qi, H. Li et al., Serum microRNA expression profile distinguishes enterovirus 71 and coxsackievirus 16 infections in patients with hand-foot-and-mouth disease, PLoS One 6 (2011), e27071-1-e27071-6.
34. M. Osaki, F. Takeshita and T. Ochiya, MicroRNAs as biomarkers and therapeutic drugs in human cancer, Biomarkers 13 (2008), 658-670.
35. C.M. Croce, Causes and consequences of microRNA dysregulation in cancer, Nat. Rev. Genet. 10 (2009), 704-714.
36. J. Lu, G. Getz, E.A. Miska et al., MicroRNA expression profiles classify human cancers, Nature 435 (2005), 834-838.
37. A. Esquela-Kerscher and F.J. Slack, Oncomirs-microRNAs with a role in cancer, Nat. Rev. Cancer 6 (2006), 259-269.
38. H. Osada and T. Takahashi, MicroRNAs in biological processes and carcinogenesis, Carcinogenesis 28 (2007), 2-12.
39. A. Lujambio and S.W. Lowe, The microcosmos of cancer, Nature 482 (2012), 347-355.
40. S. Erster, M. Mihara, R.H. Kim et al., In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA that can precede p53 target gene activation, Mol. Cell Biol. 24 (2004), 6728-6741.
41. D.R. Green and G. Kroemer, Cytoplastmic functions of the tumor suppressor p53, Nature 458 (2009), 1127-1130.
42. B. Hoffman and D.A. Liebermann, Apoptotic signaling by c-MYC, Oncogene 27 (2008), 6462-6472.
43. J. Klefstrom, E.W. Verschuren and G. Evan, c-MYC augments the apoptotic activity of cytosolic death receptor signalling proteins by engaging the mitochondrial apoptotic pathway, J. Biol. Chem. 277 (2002), 43224-43232.
44. P. S elengaris, M. Khan and G.I. Evan, Suppression of Mic-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression, Cell 109 (2002), 321-334.
45. T.G. Cotter, Apoptosis and cancer: the genesis of research field, Nat. Rev. Cancer 9 (2009), 501-507.
46. S.S. Chim, T.K. Shing, E.C. Hung et al., Detection and characterization of placental microRNAs in maternal plasma, Clin Chem. 54 (2008), 482-490.
47. R. Etzioni, N. Urban, S. Ramsey et al., The case for early detection, Nat. Rev. Cancer 3 (2003), 243-252.
48. S. Gilad, E. Meiri, Y. Yogev et al., Serum microRNAs are promising novel biomarkers, PLoS One 3 (2008), e3148-1-e3148-7.
49. C.H. Lawrie, S. Gal, H.M. Dunlop et al., Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma, Br. J. Haematol. 141 (2008), 672-675.
50. P.S. Mitchell, R.K. Parkin, E.M. Kroh et al., Circulating microRNAs as stable blood-based markers for cancer detection, Proc. Natl. Acad. Sci. USA 105 (2008), 10513-10518.
51. X. Chen, Y. Ba, L. Ma et al., Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases, Cell Res. 18 (2008), 997-1006.
52. R. Etzioni, N. Urban, S. Ramsey et al., The case for early detection, Nat. Rev. Cancer 3 (2003), 243-252.
53. R.V. Kartha and S. Subramanian, MicroRNAs in cardiovascular diseases: biology and potential clinical applications, J. Cardiovasc. Transl. Res. 3 (2010), 256-270.
54. P. Willeit, A. Zampetaki, K. Dudek et al., Circulating microRNAs as novel biomarkers for platelet activation, Circ. Res. 112 (2013), 595-600.
55. S. Erener, M. Mojibian, J.K. Fox et al., Circulating miR-375 as a biomarker of-cell death and diabetes in mice, Endocrinology 154 (2013), 603-608.
56. E. Sturchio, A. Amadori, J. Businaro et al., Possible use of microRNAs as biomarkers for monitoring of workers exposed to asbestos, G Ital. Med. Lav. Ergon. 3 (2012), 571-573.
57. E. Sturchio, T. Colombo, N. Carucci et al., Molecular biomarkers in workers and population exposed to inorganic arsenic: preliminary study in vitro, G Ital. Med. Lav. Ergon. 3 (2012): 678-681.
58. J. Hu, Z. Wang, C.J. Tan et al., Plasma microRNA, a potential biomarker for acute rejection after liver transplantation, Transplantation 95 ( 2013), 991-999
59. V. Bihrer, M. Friedrich-Rust, B. Kronenberger et al., Serum miR-122 as a biomarker of neuroinflammation in patients with chronic hepatitis C virus infection, Am. J. Gastroenterol. 106 (2011), 1663-1669.
60. B. Li, C. Hartono, R. Ding et al., Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine, N Engl. J. Med. 344 (2001), 947-954.
61. A. Bonauer, G. Carmona, M. Iwasaki et al., MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice, Science 324 (2009), 1710-1713.
62. Y. Zhang, Y. Jia, R. Zheng et al., Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases, Clin. Chem. 56 (2010), 1830-1838.
63. A.A. Bravo, S.G. Sheth and S. Chopra, Liver biopsy, N. Engl. J. Med. 344 (2001), 495-500.
64. R. Waqar, R. Farid, Qiuwei Pan et al., Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation, Liver Transplantation 18 (2012), 290-297.
65. D.P. Silvia, C. Claudia, M.L. Emma et al., Characterization of microRNA expression profiles in normal and osteoarthritic human chondrocytes, BMC Musculoskelet Disord. 13 (2012), 144-156.
66. S.W. Jones, G. Watkins, N. Le Good et al., The identification of differentially expressed microRNA in osteoarthritic tissue that modulate the production of TNF-alpha and MMP13, Osteoarthr Cartilage 17 (2009), 464-472.
67. D. Iliopoulos, K.N. Malizos, P. Oikonomou and A. Tsezou, Integrative microRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory networks, PLoS One 3 (2008), e3740-1-e3740-10.